We previously reported 2-[2-(4-tert-butylphenyl)ethyl]-N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide 2 as on orally available monoacylglycerol acyltransferase 2 (MGAT2) inhibitor which exhibited an in vivo efficacy at an oral dose of 100 mg/kg in a mouse oral lipid tolerance test. Further optimization of compound 2 to improve the intrinsic potency culminated in the identification of compound 11. Compound 11 showed a >50-fold lower IC50 against human MGAT2 enzyme than 2. Oral administration of 11 at a dose of 3 mg/kg in the oral lipid tolerance test resulted in significant suppression of triglyceride synthesis.
我们之前报道了2-[2-(4-
叔丁基苯基)乙基]-N-(4-
氟苯基)-1,2,3,4-
四氢异喹啉-6-磺酰胺2,这是一种口服可用的单酰
甘油酰基转移酶2(MGAT2)
抑制剂,在小鼠口服脂质耐受测试中以100 mg/kg的剂量表现出体内疗效。对化合物2进行进一步优化以提高内在效力,最终确定了化合物11。化合物11对人类MGAT2酶的IC50值比2低超过50倍。在口服脂质耐受测试中以3 mg/kg的剂量口服给药11导致三酸
甘油脂合成显著抑制。